
Camilla Heiniö

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3558565/publications.pdf Version: 2024-02-01



<u>CAMILLA Η ΕΙΝΙΑ</u>

#	Article	IF	CITATIONS
1	Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. Oncolmmunology, 2022, 11, 2028960.	4.6	14
2	Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. Frontiers in Immunology, 2022, 13, 794251.	4.8	16
3	Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression. Oncolmmunology, 2022, 11, .	4.6	20
4	Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes. Cancer Gene Therapy, 2021, 28, 442-454.	4.6	15
5	Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. Cells, 2021, 10, 978.	4.1	16
6	Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. Frontiers in Immunology, 2021, 12, 706517.	4.8	13
7	Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Molecular Therapy - Oncolytics, 2020, 17, 47-60.	4.4	35
8	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncolmmunology, 2020, 9, 1761229.	4.6	22
9	Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. , 2020, 8, e000188.		45
10	TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. Cells, 2020, 9, 798.	4.1	26
11	Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs. Human Gene Therapy, 2019, 30, 740-752.	2.7	3